LIFECORE BIOMEDICAL ($LFCR) posted quarterly earnings results on Thursday, April 3rd. The company reported earnings of -$0.19 per share, missing estimates of -$0.15 by $0.04. The company also reported revenue of $35,150,000, beating estimates of $33,893,580 by $1,256,420.
You can see Quiver Quantitative's $LFCR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
LIFECORE BIOMEDICAL Insider Trading Activity
LIFECORE BIOMEDICAL insiders have traded $LFCR stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $LFCR stock by insiders over the last 6 months:
- CHRISTOPHER S KIPER has made 2 purchases buying 1,463,414 shares for an estimated $5,999,997 and 0 sales.
- PARTNERS SMALL CAP VALUE LP I WYNNEFIELD has made 2 purchases buying 292,683 shares for an estimated $1,200,000 and 0 sales.
- PAUL JOSEPHS (Chief Executive Officer) purchased 17,000 shares for an estimated $97,580
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
LIFECORE BIOMEDICAL Hedge Fund Activity
We have seen 38 institutional investors add shares of LIFECORE BIOMEDICAL stock to their portfolio, and 38 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LEGION PARTNERS ASSET MANAGEMENT, LLC added 1,463,414 shares (+49.3%) to their portfolio in Q4 2024, for an estimated $10,873,166
- GREENHAVEN ROAD INVESTMENT MANAGEMENT, L.P. added 1,387,362 shares (+62.2%) to their portfolio in Q4 2024, for an estimated $10,308,099
- 325 CAPITAL LLC added 792,681 shares (+57.9%) to their portfolio in Q4 2024, for an estimated $5,889,619
- INVESCO LTD. added 555,607 shares (+inf%) to their portfolio in Q4 2024, for an estimated $4,128,160
- DEUTSCHE BANK AG\ removed 290,286 shares (-91.9%) from their portfolio in Q4 2024, for an estimated $2,156,824
- DCF ADVISERS, LLC added 251,511 shares (+87.2%) to their portfolio in Q4 2024, for an estimated $1,868,726
- WYNNEFIELD CAPITAL INC removed 215,763 shares (-4.4%) from their portfolio in Q4 2024, for an estimated $1,603,119
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
LIFECORE BIOMEDICAL Analyst Ratings
Wall Street analysts have issued reports on $LFCR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Craig-Hallum issued a "Buy" rating on 11/22/2024
To track analyst ratings and price targets for LIFECORE BIOMEDICAL, check out Quiver Quantitative's $LFCR forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
